Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy

Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy: Prospective Longitudinal Study Over 12 Months.

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01841814

Acronym

LYMPHOS

Enrollment

Registered

2013-04-29

Start date

2013-04-30

Completion date

2013-04-30

Last updated

2016-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Osteoporosis

Keywords

Lymphoma, Osteoporosis, Chemotherapy, Patient with

Brief summary

The purpose of this study is to assess changes of bone mineral density (BMD) at 12 months during the therapeutic management of patients with lymphoma.

Interventions

RADIATIONBone densitometry.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Subjects aged 18 to 80 with lymphoma, * Histological diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin lymphoma (NHL) of follicular or aggressive (large cell or other), * Patients who have not yet started their chemotherapy or who have started for less than a month * Patient has signed informed consent.

Exclusion criteria

* Pathological fractures at the time of initial diagnosis of lymphoma, * Compression of neurological epidural, * Patients receiving treatment for osteoporosis (including bisphosphonates, selective modulators of estrogen receptor, calcitonin and parathyroid hormone Teriparatide). * Discovery of osteoporosis or osteopenia fracture during the initial evaluation requiring the establishment of an osteoporosis treatment, * Radiotherapy to the lumbar spine or hip studied, * Location of bone lymphoma in the lumbar spine or hip studied, * History of disorders affecting bone metabolism (prostate cancer with androgen, stomach cancer, hyperparathyroidism, hyperthyroidism, uncontrolled ...) * A person incapable of giving consent personally, * Pregnant or breastfeeding women, * Protected Person (under guardianship) * Patient not affiliated with a social security system.

Design outcomes

Primary

Measure	Time frame	Description
Measurement of bone mineral density (BMD).	Change from Baseline of bone mineral density at 12 months.	Patients will have a review of bone densitometry.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026